Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
SourceDiabetes, Obesity & Metabolism, 21, 3, (2019), pp. 499-508
Article / Letter to editor
Display more detailsDisplay less details
Diabetes, Obesity & Metabolism
SubjectAll institutes and research themes of the Radboud University Medical Center; Radboudumc 6: Metabolic Disorders RIMLS: Radboud Institute for Molecular Life Sciences
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.